Navigation Links
S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets
Date:1/6/2009

S*BIO Receives $25 Million Upfront Payment and Equity Investment and Eligible to Receive Additional $525 Million in Option & License Fees and Milestone Payments

SINGAPORE, Jan. 6 /PRNewswire/ -- S*BIO Pte Ltd today announced that the company has entered into a Development Collaboration, and Option & License Agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize S*BIO's novel JAK2 inhibitors, SB1518 and SB1578.

Under the terms of the agreement, S*BIO is eligible to receive up to $550 million in combined equity purchase, option & license fees, and development and sales milestone payments. This includes an upfront payment and upfront equity purchase totaling $25 million. S*Bio is also eligible to receive up to double digit royalties on any sales.

S*BIO will perform all the clinical development activities for SB1518 and preclinical to clinical development activities for SB1578 during the option period. Onyx can elect to exercise its exclusive options for SB1518 and SB1578 at certain predetermined stages of development for each product separately and independently. Each option converts into an exclusive license for development and commercialization rights for SB1518 and SB1578 in all indications in the United States, Canada and Europe where Onyx will assume all of the associated development costs. S*BIO has a co-funding option with respect to these development costs in return for enhanced royalties on any future product sales. S*BIO retains rights to develop and commercialize SB1518 and SB1578 in the rest of the world.

The development of SB1518 will initially focus on the treatment of myelofibrosis and other myeloproliferative diseases. JAK2 inhibitors are implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases.

"We are pleased to work with Onyx Pharmaceuticals and increase available reso
'/>"/>

SOURCE S*BIO
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
2. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. MHA Announces Pegeen Butterfield, RN as Senior Vice President of Trade Relations
5. IMRIS announces first IMRISneuro project in Australia
6. Akrimax Pharmaceuticals Announces Manufacturing Partnership
7. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
8. American Asthma Foundation Announces Breakthrough Discovery
9. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
10. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
11. DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... Houston, TX (PRWEB) , ... August 29, 2015 ... ... settlement allows the company to freely market and sell Arterosil and Arterosil HP, ... Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the ...
(Date:8/28/2015)... Richey, FL (PRWEB) , ... August 28, 2015 , ... ... many potential workers are qualified for the position they are applying for, they are ... of this, many employers are considering altering drug testing policies in order to be ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... ... ... Hayes, Inc., the nation’s leading health technology research and consulting company, today announced that ... has joined the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC). The MEDCAC ...
... is not a replacement for HIV-specific drugs, researchers say , ... people who are infected with both HIV-1, a strain of ... benefit in more than one way by taking a herpes ... appears to also slow the progression of HIV. , ...
... , , , , , , ... ( SVA),a leading China -based vaccine manufacturer, today announced the ... land use,rights. The total consideration for the purchase is approximately ... working capital. The,initial payment of RMB56.5 million ( $8.3 ...
... ... covers annual dental cleanings , ... Canton, OH (PRWEB) February 15, 2010 -- Preventive care can serve as the best protection ... Pet Health Insurance makes this care even easier for pet parents to afford., , ,About ...
... , ... lawyers scrutinize the defect which causes Toyota made cars and trucks to accelerate when the ... ... of almost 2.3 million vehicles on January 21, because the company learned that accelerator pads ...
... ... CO2 fire extinguishers and extinguishers with frost-free horns. , ... Dartford, Kent (PRWEB) February 15, 2010 -- Fire ... fire extinguishers actually pose some safety hazards of their own: If incorrectly handled ...
Cached Medicine News:Health News:Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 3Health News:Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets 2Health News:Toyota Recalls Millions of Defective Vehicles 2Health News:Toyota Recalls Millions of Defective Vehicles 3Health News:Fire Protection Online Resolves Safety Concerns with CO2 Fire Extinguishers 2
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by AstraZeneca plc, quetiapine ... important drug for the treatment of schizophrenia. Approved ... was listed in the Catalogue of Drugs for ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... the novel,selective relaxant binding agent (SRBA) being developed ... neuromuscular blockade as,compared to neostigmine in the Phase ... Spectrum, faster recovery from profound neuromuscular,blockade compared to ... were presented today at the 2007 annual meeting ...
... safety of nebulized,formoterol fumarate and safety/ efficacy of concomitant use with ... ... 16 Dey, L.P., a subsidiary of Mylan,Inc. (NYSE: MYL ... the annual scientific assembly of the American College of,Chest Physicians (ACCP) ...
Cached Medicine Technology:Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 2Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 3Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 4Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 5Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 2Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 3Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 4Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 5
... for eyecare professionals- Winx Pro ... practice management system, using the ... Pro is a complete solution ... effectively managing the administrative, financial ...
The Advia 60 is designed to deliver powerful performance in a small package....
The XT-2000i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
Ac.T 5diff CP allows quick and direct access to a closed sample tubea feature that reduces manual sample handling, saves time and enhances safety by eliminating operators exposure to biohazards....
Medicine Products: